Vishwas Setia
Fortune : 10 M $ au 31/05/2026
Fortune : 10 M $ au 31/05/2026
Vishwas Setia is currently Chief Financial Officer at MapLight Therapeutics, Inc. since 2024.
Formerly, Mr. Setia was an Investment Banking Summer Associate at Merrill Lynch & Co., Inc. in 2013.
Mr. Setia earned an MBA from Kellogg School of Management in 2014 and completed undergraduate studies at Delhi College of Engineering.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 06/05/2026 | 356 256 ( 0,84 % ) | 10 M $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| MAPLIGHT THERAPEUTICS, INC. | Directeur Financier/CFO | 18/03/2024 |
| Sociétés | Poste | Fin |
|---|---|---|
Merrill Lynch & Co., Inc. /Old/
Merrill Lynch & Co., Inc. /Old/ Investment Banks/BrokersFinance Provides wealth management, securities trading and sales, corporate finance and investment banking services | Corporate Officer/Principal | 01/08/2013 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
Merrill Lynch & Co., Inc. /Old/
Merrill Lynch & Co., Inc. /Old/ Investment Banks/BrokersFinance Provides wealth management, securities trading and sales, corporate finance and investment banking services | Finance |
Delhi College of Engineering
Delhi College of Engineering Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kellogg School of Management
Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics for debilitating central nervous system disorders | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national